Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prion-like transmission and propagation of human β-amyloid to the bank vole rodent model.

Acta neuropathologica·2026

Same author

Prevalence of Lewy body pathology and phenotypic associations in patients with mild cognitive impairment: Evidence from the Interceptor study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026

Same author

Mild cognitive impairment-to-Alzheimer's dementia progression risk: the contribution of the Interceptor project.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same author

D178N prion protein mutation endows RML prions with new strain properties that do not mimic human genetic prion diseases.

Acta neuropathologica·2026

Same author

Neuroimaging and Pathology Biomarkers in Parkinson's Disease and Parkinsonism.

Brain sciences·2026

Same author

Plasma extracellular vesicles and phosphorylated tau 181 as early biomarkers of cognitive impairment in Alzheimer's dementia.

Alzheimer's research & therapy·2026

Search research articles

Related Experiment Video

Updated: May 7, 2026

Prion Safety Laboratory Swipe Test

Prion Safety Laboratory Swipe Test

Published on: February 14, 2025

Therapy in prion diseases.

Gianluigi Forloni¹, Vladimiro Artuso, Ignazio Roiter

¹IRCCS Istituto di Ricerche Farmacologiche "Mario Negri" Via La Masa 19, 20156 Milano, Italy. forloni@marionegri.it.

Current Topics in Medicinal Chemistry

|September 25, 2013

Summary

Developing effective therapies for prion diseases (transmissible spongiform encephalopathies) is challenging due to disease complexity and limited treatment options. Early diagnosis and intervention are crucial for future therapeutic success in these neurodegenerative disorders.

More Related Videos

Protein Misfolding Cyclic Amplification of Prions

Protein Misfolding Cyclic Amplification of Prions

Published on: November 7, 2012

Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material

Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material

Published on: September 29, 2017

Related Experiment Videos

Last Updated: May 7, 2026

Prion Safety Laboratory Swipe Test

Prion Safety Laboratory Swipe Test

Published on: February 14, 2025

Protein Misfolding Cyclic Amplification of Prions

Protein Misfolding Cyclic Amplification of Prions

Published on: November 7, 2012

Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material

Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material

Published on: September 29, 2017

Area of Science:

Neurobiology
Neurodegenerative Diseases
Protein Misfolding Disorders

Background:

Prion diseases, or transmissible spongiform encephalopathies (TSE), share neurobiological mechanisms with other protein misfolding disorders like Alzheimer's and Parkinson's.
Soluble oligomers of misfolded proteins are implicated as key pathogenic agents, leading to the concept of 'oligomeropathies'.
Despite advances, effective therapies for TSEs remain elusive due to challenges in clinical translation and trial design.

Purpose of the Study:

To review the current state of therapeutic strategies for prion diseases.
To highlight common challenges and molecular targets shared with other neurodegenerative disorders.
To discuss the potential of emerging therapeutic approaches and the importance of early diagnosis.

Main Methods:

Review of experimental and clinical studies on TSE therapies.
Analysis of molecular targets, including the prion protein (PrP) and its pathological forms (PrPSc).
Evaluation of therapeutic strategies such as small molecules, immunization, and PrPC modulation.

Main Results:

Several compounds have shown efficacy in preclinical models, but few have translated to clinical success.
Clinical trials with quinacrine, pentosan polysulfate, and doxycycline yielded unsatisfactory results.
Preclinical studies demonstrate potential for anti-PrP antibodies, mucosal vaccination, and targeting PrP oligomers.

Conclusions:

Prion disease therapy faces significant hurdles, including rapid progression and heterogeneity.
Targeting PrP oligomers and modulating PrPC are promising avenues.
Early diagnosis for preclinical intervention is the most realistic strategy for effective TSE treatment.